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Abstract 
The purpose of this research is to evaluate the necessity of using heparin in UltraTag™ RBC kits 
used for nuclear medicine studies. Methods: Non-heparinized blood (n=15) and heparinized 
blood (n=15) were added into UltraTag™ RBC kits. The samples were evaluated for 
macroscopic blood clots and microscopic platelet clumping. Control groups with heparin (n=15) 
and control groups without heparin (n=15) were used to help evaluate the effectiveness of the 
anticoagulant properties within the UltraTagTM RBC kits (sodium citrate) and to evaluate if that 
played a role in preventing blood clots/clumps. To detect macroscopic clotting the wooden 
applicator stick method was used. To detect microscopic platelet clumping blood smears were 
evaluated using a light microscope. The number of macroscopic clots and microscopic platelet 
clumping were compared between the two individual samples. Fisher’s Exact Test was used to 
evaluate the significance of the data.  Results: Macroscopically for the UltraTagTM RBC kits, 
two of fifteen UltraTagTM RBC Non-heparinized vials clotted and zero of fifteen UltraTagTM 
RBC Heparin vials clotted. Macroscopically for the control group two of fifteen Control Non-
heparinized tubes clotted and zero of fifteen Control Heparin tubes clotted. Microscopically for 
the Ultra-TagTM RBC kits three of the fifteen UltraTagTM RBC Non-heparinized vials clumped 
and three of the fifteen UltraTagTM RBC Heparin vials clumped. Microscopically for the control 
group fifteen of fifteen Control Non-heparinized tubes clumped and ten of the fifteen Control 
Heparin tubes clumped. Conclusion: When heparin isn’t used, Ultra-TagTM RBC kits are more 
likely to form macroscopic clots. Heparin should always be used when making an Ultra-TagTM 
RBC kit for nuclear medicine studies.  
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Introduction 
In nuclear medicine some studies require blood to be withdrawn from the patient, 
radiolabeled via an UltraTag™ Red Blood Cell (RBC) kit and then injected back into the patient 
for imaging. Heparin is added to the syringe prior to withdrawing the blood from the patient to 
prevent blood clots from forming during the radiolabeling process. This research was done to 
evaluate the necessity of using  heparin when radiolabeling blood using UltraTagTM RBC kits.  
The recommended amount of heparin is 10-15 units per mL of blood (1). When tagging 
blood heparin is an anticoagulant that reduces the chances of blood clotting(2). The body also 
has its own fibrinolytic system responsible for lysing clots. This fibrinolytic system was 
discovered in the beginning of the 20th century by Niewiarowski, who showed that the end 
products of fibrinolysis inhibit the process of coagulation(3). The UltraTag™ RBC kit also 
contains sodium citrate. Sodium citrate is another common anticoagulant used in vitro (4). 
Despite the presence of sodium citrate in the kit and the body’s own fibrinolytic system, the 
package insert states that the syringe used to draw the blood must contain heparin before 
radiolabeling the blood in the UltraTag™ RBC kit. 
Common nuclear medicine studies that use UltraTag™ RBC kits are Multi Gated 
Acquisition (MUGA) studies and Gastrointestinal (GI) Bleed studies. An indication for a MUGA 
study is to evaluate left ventricular (LV) function at baseline before chemotherapy(5). An 
indication for a GI Bleed study is to detect the presence and site of an acute GI bleed (5).  While 
it is important to prevent blood clots for the health of the patient, it is also important for the 
accuracy of the study. If the radiolabeled blood containing a blood clot was injected into the 
patient the blood clot could potentially get caught in a vein blocking the rest of the radiolabeled 
blood from getting to the appropriate area.  
In this study we evaluated clots in two ways:  macroscopic clots and microscopic platelet 
clumping.  Macroscopic clots are visible to the naked eye. They appear as large mucous-like 
threads in the specimen. These mucous-like threads are formed by the aggregation and 
accumulation of platelets and the formation of fibrin from fibrinogen. One of the most common 
side effects from a macroscopic blood clot is an acute pulmonary embolism. Pulmonary emboli 
account for 50,000 deaths annually(6). Microscopic platelet clumping can only be seen with a 
microscope. They are referred to as clumping and not clots because microscopically only 
aggregated platelets are visualized. There is no macroscopic sign of mucous threads or fibrin 
formation. Both clotting and clumping could potentially lead to pulmonary embolism, stroke, 
and deep vein thrombosis.  
The purpose of this research was to evaluate the necessity of using heparin when 
preparing UltraTag™ RBC kits.  
Materials and Methods 
 Subjects. This research study included 15 volunteer subjects. Institutional Review Board 
(IRB) approval was obtained and HIPAA guidelines were followed. There were no exclusion 
criteria regarding the volunteer subjects. A flyer was made and sent out to the undergraduate 
radiologic and imaging science students at the university requesting volunteers to participate in 
this study. The volunteer subjects were picked on a first come first serve basis in regards to 
responding to the flyer. Of the 15 volunteers 12 were students, two were nuclear medicine 
technologists, and one was a nuclear pharmacist.   
 Supplies. The supplies, for each volunteer subject, included: two UltraTagTM RBC kits, 
40 units of unfractionated heparin (UFH), 74 megabecquerels (MBq) of Technetium-99m 
Sodium Pertechnetate, eight microscope slides, eight wooden applicator sticks, one IV starter kit 
with a 20 gauge needle, two SmartSite® vented vial access devices, two BD Falcon Round-
Bottom Tubes with lids, eleven 3mL syringes with an attaching 20 gauge needle, a Dose 
Calibrator, a lead shield, a Geiger Mueller survey meter, Nikon Eclipse Ni-U microscope, Hema-
Tek® I 1000, Wright-Giemsa Pack, and pliers.  
Procedures. A 20-gauge IV was started on each volunteer. Four samples of blood were 
drawn and labelled as follows: 
1. UltraTagTM RBC Heparin:  Three mL of blood was drawn into a syringe 
containing 30 units of heparin. 
2. UltraTagTM Non-heparin:  Three mL of blood was drawn into an empty syringe. 
3. Control Heparin:  One mL of blood was drawn into a syringe containing 10 units 
of heparin. 
4. Control Non-heparinized:  One mL of blood was drawn into an empty syringe. 
 
The two controls were done to help evaluate the effectiveness of the sodium citrate 
contained within the UltraTagTM RBC kits at preventing blood clots/clumps. The blood from the 
two UltraTagTM syringes were each added in a separate UltraTagTM vial (heparin and non-
hepranized).  The blood from the two control groups were each added into a separate empty tube 
(heparin and non-hepranized).  The UltraTagTM RBC Heparin vial and UltraTagTM RBC Non-
heparinized vial were radiolabeled following the package insert guidelines, using approximately 
37MBq of Technetium-99m Sodium Pertechnetate.  
All four samples of blood were evaluated for macroscopic clots and microscopic platelet 
clumping.  To evaluate for macroscopic clots the wooden applicator stick method was used. Two 
wooden sticks were held together like chop sticks and swirled around in the UltraTagTM RBC 
kits and Control tubes. The wooden sticks were then gently pulled up the side of the UltraTagTM 
RBC kits and Control tubes and once the ends of the wooden sticks were visible they were 
analyzed for macroscopic clots. If a macroscopic clot was present then a yes was recorded on the 
data sheet. If a macroscopic clot was not present then a no was recorded on the data sheet. Figure 
1 shows an example of a negative macroscopic clot and a positive macroscopic clot. To evaluate 
for microscopic platelet clumping a blood smear was prepared. A drop of blood was placed onto 
a microscope slide and then another microscope slide was placed directly on top of the drop of 
blood and the slides were pulled across each other making a thin smear. Eight microscope slides 
were labeled for the blood smearing method; two for each of the four samples. Two slides were 
labeled HV for the UltraTagTM RBC Heparin vial, two slides were labeled HT for the Control 
Heparin tube, two slides were labeled XV for the UltraTagTM RBC Non-heparinized vial, and two 
slides were labeled XT for the Control Non-heparinized tube. Blood smears were prepared using 
a similar methodology for UltraTagTM RBC Heparin vial, UltraTagTM RBC Non-heparinized 
vial, Control Heparin tube, and Control Non-heparinized tube and the blood smearing method 
was implemented. This entire procedure was repeated for all 15 subjects.  
The slides were stained and analyzed by a medical laboratory scientist. The slides were 
stained with a Wright-Giemsa Pack using a Hema-Tek® I 1000.  The slides were evaluated by 
the medical laboratory scientist using a Nikon Eclipse Ni-U microscope. Each slide was analyzed 
by looking at 20 fields of view at 500x oil magnification. The fields of view were chosen at 
random to provide a fair representation of the slide. If the slide showed an area of platelet 
clumping then a yes would be recorded on the data sheet and if the slide showed no platelet 
clumping then a no would be recorded on the data sheet. Figure 2 shows an example of negative 
microscopic platelet clumping and positive microscopic platelet clumping. 
 Statistical Tests. To evaluate the data, Fisher’s Exact Test was used. A p-value of less 
than 0.05 represents statistical significance and allowed rejection of the null hypothesis. The null 
hypothesis was that there is no difference in the prevalence of blood clotting/clumping when 
heparin is used compared to when heparin is not used in an UltraTagTM RBC kit.  The alternate 
hypothesis was that there is a difference in the prevalence of blood clotting/clumping when 
heparin is used compared to when heparin is not used in an UltraTagTM RBC kits.  
Results 
 Subjects. Of the 15 volunteer subjects three were male and twelve were female. Nine 
volunteer subjects ranged in ages of 18-25 years old and six volunteer subjects ranged in ages of 
26-65 years old.  
 Outcome. The UltraTagTM RBC kits with heparin had zero macroscopic clots and three 
had microscopic platelet clumping.  The non-heparinized UltraTagTM kits had two macroscopic 
clots and three had microscopic platelet clumping.  The control group with heparin had zero 
macroscopic clots and ten had microscopic platelet clumping.  The control group without heparin 
had two had macroscopic clots and ten microscopic platelet clumping. 
 For the UltraTagTM RBC kits, macroscopically, the p-value was 0.48 and microscopically 
the p-value was 1.0. For the control group, macroscopically the p-value was 0.98. In each of 
these cases there is not enough evidence to reject the null hypothesis.  Statistically, there is no 
difference macroscopically and microscopically between the UltraTagTM RBC Heparin vials and 
the UltraTagTM RBC Non-heparinized vials and there is no difference macroscopically between 
the Control Heparin tubes and Control Non-heparinized tubes.  
Microscopically for the control group the p-value was 0.04. The null hypothesis is 
rejected in favor of the alternate hypothesis. There was a statistically significant difference in 
microscopic platelet clumping for control group between heparinized and non-heparinized 
samples. The results of the Fisher’s Exact Test are given in Tables 1 and 2. 
Incidental findings. The raw data is seen in Table 3. Three volunteers (4, 9 and 13) had 
microscopic platelet clumping present in the heparinized UltraTagTM kit that was not seen in the 
non-heparinized UltraTagTM RBC kit.   
Discussion 
If macroscopic clots are seen, the microscopic clumps must also be present. The reverse 
is not true; you can have microscopic clumps but not have macroscopic clots. If macroscopic 
clots were present, then microscopic clumps were automatically recorded as yes. When 
comparing the control group with the UltraTagTM RBC group it appears that the anticoagulant 
properties within the UltraTagTM RBC kits (sodium citrate) are effective at preventing 
microscopic platelet clumping but not effective enough to stop macroscopic clots.  Although not 
statistically significant, it appears that heparin is necessary to stop macroscopic clots from 
forming due to two clots forming in the absence of heparin compared to zero with heparin. There 
is a statistically significant difference in microscopic platelet clumping in the control group. A 
larger sample size could get statistically significant results regarding the other samples.  
Although the data did not show statistically significant results it is still clinically 
significant. Ultimately injecting a macroscopic clot could cause detrimental side effects to the 
patient and effect the accuracy of the study. Further research should be done microscopically 
taking more samples of blood from the UltraTagTM RBC kits to test for microscopic clumping.  
A limitation to the study is the time frame during which the blood was drawn and when it 
was exposed to the sodium citrate in the UltraTagTM RBC kit. Clotting is a time dependent 
action. This is a mute point with the heparin kits because the heparin was already in the syringe 
when the blood was drawn.   
Conclusion 
Ultra-TagTM RBC kits can produce macroscopic blood clots without heparin.  Heparin 
should always be used when making an Ultra-TagTM RBC kit for nuclear medicine studies.  
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 Figure 1:  Image A shows an example of no macroscopic clot.  Image B shoes an 
example of a macroscopic clot 
 
 
Figure 2:  Image A shows an example of no microscopic platelet clumping.  
Image B shoes an example of microscopic platelet clumping. 
 
 
 
 
 
 
 
  
 
UltraTag® 
 With Heparin Without Heparin P-value 
Macroscopic Clotting  0/15 (0%) 2/15 (13%) P = 0.48 
Microscopic Clumping  3/15 (20%) 3/15 (20%) P = 1.0 
Table 1:  Comparison of positive results with and without heparin in UltraTag® kits 
Control Group 
 With Heparin  Without Heparin  
Macroscopic Clotting 0/15 (0%) 2/15 (13%) P = 0.48 
Microscopic Clumping 10/15 (67%) 15/15 (100%) P = 0.04 
Table 2:  Comparison of positive results with and without heparin in the control group 
 
Volunteer UltraTag®  
with heparin 
UtraTag® 
without heparin 
Control  
with heparin 
Control  
without heparin 
1 - M and u u u 
2 - - - u 
3 - - - u 
4 u - - u 
5 - - - M and u 
6 - - u u 
7 - - u u 
8 - - u u 
9 u - - u 
10 - - u u 
11 - u u u 
12 - - u M and u 
13 u - u u 
14 - M and u u u 
15 - - u u 
u = microscopic platelet clumping   M = macroscopic clotting 
Table 3: Clotting and clumping results by volunteer 
 
